格隆汇2月15日｜黑龙江省人民政府办公厅印发《黑龙江省支持生物制造产业高质量发展若干政策措 施》，其中提到，支持开展核心技术攻关。坚持科技成果转化导向，围绕生物制造关键核心技术和前沿 方向，部署实施一批重点研发计划项目，支持创新药械、核心菌种、生物育种、生物化工等领域技术攻 关，经评审通过的项目，按有关规定给予省级财政资金支持。支持企业创新能力提升。鼓励生物制造企 业加大研发投入，对研发投入50万元以上且符合条件的，按照企业年度研发投入存量和增量部分给予不 同比例补助，省、市按1∶1比例出资。 ...

（来源：市场星报） 星报讯 2月12日上午，记者从安徽省人民政府新闻办公室召开的新闻发布会上获悉，近日，省商务厅、 省科技厅、省卫生健康委、省药监局、合肥海关等五部门联合印发了《关于支持中国（安徽）自由贸易 试验区合肥片区生物医药产业链关键环节集成创新试点举措》（以下简称《试点举措》），围绕支持合 肥片区生物医药产业研发、生产、审评、应用等关键环节，从4方面提出20项具体举措，这是安徽自贸 试验区设立以来首个产业链集成创新措施。 《试点举措》主要包含四个方面内容。一是聚焦研发环节，激活创新能力。包括研究制定进口研发用物 品"白名单"试点方案；持续优化特殊物品入境联合监管机制；争取国家医疗领域扩大开放试点；支持人 工智能赋能医药全产业链发展；支持片区内医疗机构开展临床试验等8项举措。二是聚焦生产环节，推 动项目落地。包括探索开展生物制品分段生产试点；加强与海南博鳌乐城国际医疗旅游先行区对接合 作；支持加快推动规划环评与项目环评联动等3项举措。三是聚焦审评环节，优化审批服务。包括支持 合肥市推进药品审评核查分中心建设；进一步完善合肥经开区、高新区医药创新柔性服务站建设等2项 举措。四是聚焦应用环节，加快产品推广。 ...

Core Insights - The healthcare payment system in China is transitioning from a "basic medical insurance" model to a "basic medical insurance + commercial insurance" multi-collaboration model, creating new growth momentum in the healthcare service sector and increasing demand for professional commercial insurance services [2][3] - The rapid expansion of the innovative pharmaceutical and medical device market, projected to grow from RMB 92.3 billion in 2019 to RMB 162 billion by 2024, with a compound annual growth rate (CAGR) of 11.9%, is driving the healthcare service sector [2] - The commercial health insurance market is expected to reach RMB 23,568 billion by 2030, with a CAGR of 15.8% from 2024 to 2030, indicating significant growth potential [2] Industry Dynamics - The dual-track growth of the healthcare payment system highlights the challenges in industry chain collaboration, with insurance companies facing constraints in talent and data, while innovative pharmaceutical companies encounter value realization bottlenecks [3] - Commercial insurance service providers are positioned as key players to address these challenges, facilitating collaboration across the industry chain [3] Key Players and Strategies - Major insurance companies like Ping An and China Pacific Insurance are enhancing their service offerings by building health management systems to improve the attractiveness and service experience of commercial insurance products [4] - Internet giants such as Ant Group leverage their large user base and technological advantages to innovate in direct payment models and digital empowerment, aiming to lower barriers for users in insurance participation and claims [4] - Specialized platform companies like Meixin Health focus on resource integration and technological empowerment, utilizing AI risk control and data platforms to connect pharmaceutical companies, insurers, and patients [5] Meixin Health's Performance - Meixin Health, as the largest multi-payment platform in China, has demonstrated a differentiated competitive advantage through its asset-light model, achieving revenue growth from RMB 1.069 billion in 2022 to RMB 2.035 billion in 2024, effectively doubling its revenue [6] - The adjusted net loss for Meixin Health has significantly narrowed from RMB 447 million to RMB 80 million, indicating a strong trend towards profitability [6] - In the first ten months of 2025, Meixin Health reported revenue of RMB 1.873 billion, a 34% year-on-year increase, with an adjusted net loss of RMB 55 million, continuing the trend of improving financial performance [6] Future Outlook - The healthcare payment sector is entering a new development cycle characterized by policy benefits, data assets, and product iteration, with commercial insurance service providers expected to see exponential growth in value as the payment ecosystem matures [7] - Meixin Health is well-positioned to solidify its market position through its business layout, platform-based operational model, technological advantages, and robust financial performance [7]

Group 1 - The core viewpoint of the news is the introduction of measures to support the high-quality development of commercial health insurance in Beijing, focusing on collaboration with the pharmaceutical industry [1][2] Group 2 - The measures propose the establishment of a collaborative development platform to enhance communication between commercial insurance companies and innovative pharmaceutical enterprises, facilitating information sharing and demand matching for innovative drugs and medical devices [1] - There is an emphasis on encouraging commercial insurance companies to include reasonably priced innovative drugs and high-value medical devices related to cancer, gene therapy, and rare diseases in their coverage [1] - The measures advocate for the innovation of payment models for innovative drugs, including exploring multi-modal payment options such as payment by efficacy and installment payments [1][2] Group 3 - The measures support the clinical application of innovative drugs by allowing them to be fast-tracked for listing without affecting the basic medical insurance self-payment rate [2] - Innovative drugs are exempt from certain restrictions and can be supplied through a "dual-channel" mechanism in designated medical institutions or contracted pharmacies [2] - Costs for eligible new drugs and technologies will not be included in the DRG payment standards and will be paid separately after review [2] Group 4 - The measures encourage an increase in investment in innovative drugs and medical devices, promoting financial support for the innovative pharmaceutical industry through various market-based investment methods [1]

Core Viewpoint - The issuance of the "Several Measures to Support the High-Quality Development of Commercial Health Insurance in Beijing" aims to promote the high-quality development of commercial health insurance and improve the multi-level medical security system in the capital [2]. Group 1: Measures for Development - The measures include six aspects focusing on enhancing insurance product innovation, encouraging the development of diverse insurance products that meet citizens' needs [1]. - There is an emphasis on deepening collaboration between commercial insurance and the pharmaceutical industry, promoting communication and cooperation to include innovative drugs and medical devices in insurance coverage [1]. - The initiative aims to improve service capabilities by increasing support for purchasing commercial insurance products and optimizing service experiences [1]. Group 2: Operational Enhancements - The measures promote a "one-stop" settlement model for medical insurance and commercial insurance, aiming to enhance service efficiency and reduce patient burden [1]. - Strengthening consumer rights protection and regulatory compliance is a key focus, with an aim to improve regulatory capabilities and market order [1]. - Establishing a cross-departmental collaborative work mechanism is intended to facilitate the orderly connection of multi-level medical security [1].

Group 1 - Shanghai's GDP is projected to grow at an average annual rate of 5% over the next five years, up from 4.9% during the "14th Five-Year Plan" period, indicating significant progress despite a seemingly small increase [1][3] - The achievement of this growth target relies on three key factors: stronger support from new drivers, greater release of core functions from five centers, and substantial backing from major projects, particularly in emerging industries [1][4] - By 2030, if the 5% growth rate is maintained, Shanghai's GDP is expected to exceed 7 trillion yuan, positioning it among the top three global cities, following New York and Los Angeles [1] Group 2 - The three leading industries in Shanghai are expected to maintain an average annual growth rate of over 10% during the "15th Five-Year Plan" period [2][3] - Key indicators for Shanghai's economic development include labor productivity exceeding 520,000 yuan per person, digital economy core industries accounting for over 20% of GDP, and R&D expenditure reaching over 5% of GDP by 2030 [2] Group 3 - The "15th Five-Year Plan" outlines a modern industrial system characterized by "2+3+6+6," focusing on advanced manufacturing and the establishment of world-class high-end industrial clusters [3][5] - The plan emphasizes the digital and green transformation of traditional industries and the acceleration of the three leading industries, which include integrated circuits, biomedicine, and artificial intelligence [4][5] Group 4 - The three leading industries have a significant driving effect on Shanghai's economy, with their combined scale surpassing 2 trillion yuan [4] - Specific strategies for the three leading industries include enhancing the capabilities of the integrated circuit sector, accelerating drug development in biomedicine, and advancing AI technologies [4][6] Group 5 - Shanghai aims to maintain a reasonable industrial proportion while focusing on enhancing quality and competitiveness in manufacturing, which is crucial for supporting technological innovation and the construction of five centers [5][6] - The city plans to solidify its industrial system and leverage existing industrial foundations to foster new growth engines and optimize resource allocation [5][6] Group 6 - The "15th Five-Year Plan" proposes the development of six emerging pillar industry clusters and anticipates six future industries, including advanced materials and quantum technology [7] - The focus on future industries includes areas such as brain-computer interfaces, controlled nuclear fusion, and biomanufacturing, which are expected to have high growth potential [7] Group 7 - Labor productivity is a key indicator for economic and social development, with a continued emphasis on improving productivity during the "15th Five-Year Plan" [9][10] - Enhancing labor productivity will depend on talent development, technological innovation, and systemic reforms to create a favorable business environment [10]

Group 1 - Shanghai aims for an average annual GDP growth rate of 5% over the next five years, up from 4.9% during the "14th Five-Year Plan" period, indicating significant progress despite a seemingly small numerical difference [1][3] - The growth strategy focuses on three key areas: stronger support from new drivers, greater release of core functions from five centers, and substantial backing from major projects, particularly in emerging industries [1][4] - The three leading industries—integrated circuits, biomedicine, and artificial intelligence—are expected to maintain an annual growth rate of over 10%, contributing significantly to Shanghai's economic development [4][5] Group 2 - By 2030, if the 5% growth target is met, Shanghai's GDP is projected to exceed 7 trillion yuan, positioning it among the top three global cities, following New York and Los Angeles [3] - The "15th Five-Year Plan" outlines specific targets, including a labor productivity exceeding 520,000 yuan per person and a digital economy's core industry value-added accounting for over 20% of GDP by 2030 [4][10] - Shanghai plans to establish a modern industrial system characterized by "2+3+6+6," focusing on advanced manufacturing and the development of six emerging pillar industries and six future industries [5][10] Group 3 - The city is committed to enhancing its international competitiveness and supporting technological innovation, with a focus on maintaining a stable industrial output value that aligns with GDP growth [7][8] - Recommendations include optimizing industrial land use and ensuring that industrial planning aligns with Shanghai's development needs, particularly in the biomedicine sector [8][9] - The emphasis on research and development is evident, with R&D expenditure expected to reach 5% of GDP by 2030, and a focus on fostering a culture of innovation among scientists and entrepreneurs [11][15]

Core Viewpoint - The approval of the "Biopharmaceutical Industry Chain Open Innovation Development Plan" by the State Council provides opportunities for Jiangsu Province to strengthen and expand its leading position in the biopharmaceutical industry during the 14th Five-Year Plan period [1] Group 1: Policy Recommendations - Strengthen integrated policy supply and enhance service effectiveness by implementing an "Excellence Cultivation Plan" for innovative pharmaceutical companies and optimizing clinical trial subsidy application processes [1] - Promote an "early intervention, rolling submission" approval pathway for innovative drugs and medical devices, and establish a "one product, one special class" service mechanism [1] - Establish a "white list" system for the import and export of research and development materials in biopharmaceuticals and streamline the approval process for drug marketing licenses and production licenses [1] Group 2: Innovation Ecosystem - Build a comprehensive innovation ecosystem to enhance core industry momentum by attracting national clinical medical research centers and major infrastructure projects to Jiangsu [1] - Accelerate the establishment of provincial smart pharmacy laboratories and leverage national university technology transfer centers to support the establishment of new R&D institutions [1] - Implement a green channel for the listing and coding of innovative medical devices and promote data governance across departments in healthcare [1] Group 3: Talent and Financial Support - Strengthen support for essential resources by establishing a joint recruitment and cross-training mechanism for top talents between research institutions and enterprises [1] - Include AI pharmaceutical algorithm engineers in the provincial key talent cultivation directory and develop a supporting system for high-end talent [1] - Innovate financing products to support the development of customized financial products such as intellectual property pledge loans and establish an international drug registration service center [1]

Core Viewpoint - The article emphasizes the importance of developing a professional talent system for "unaccompanied care services" in response to the aging population in Shanghai, highlighting the need for skilled nursing personnel and comprehensive care capabilities [2][5]. Unaccompanied Care Services - The average daily provision of "unaccompanied care services" at Zhongshan Hospital is between 1,300 to 1,400 patients, indicating a significant demand for this service [2]. - There is a shortage of qualified nursing staff with appropriate education and skills, which needs urgent attention [2]. - Recommendations include professional training for caregivers and establishing comprehensive fee standards for various levels of care, from "level II nursing" to post-stabilization care [5][6]. AI in Clinical Applications - The application of AI in clinical settings is increasingly prevalent, but many aspects are still in a "wild growth" phase, necessitating organized development and training of AI models [7]. - There is a call for administrative guidance in developing specialized AI models for specific diseases to enhance their applicability and effectiveness [7]. Innovation in Biomedicine - The article discusses the need for improved collaboration between scientific and clinical experts to drive innovation in biomedicine, particularly through AI-driven scientific discovery [9]. - The establishment of a "data factory" model is proposed to overcome data barriers and enhance drug development processes [10]. Global Access to Innovative Drugs and Devices - Suggestions include creating a "zero time difference" access channel for innovative drugs and devices in Shanghai, allowing for expedited approval processes for urgently needed clinical products [11]. - The exploration of cross-border data flow in healthcare is recommended to support international collaboration and digital therapy products [11].

Core Viewpoint - The article discusses Shanghai's strategic initiatives to enhance its industrial framework and position as a global high-end manufacturing hub, focusing on the development of key industries and the integration of traditional sectors with emerging technologies [3][4]. Group 1: Modern Industrial System - Shanghai's "14th Five-Year Plan" aims to establish a "2+3+6+6" modern industrial system, which includes promoting the digital and green transformation of traditional industries, accelerating the development of three leading industries, and focusing on six emerging pillar industry clusters [5][6]. - The three leading industries identified are integrated circuits, biomedicine, and artificial intelligence, with projected manufacturing output growth of 9.6% by 2025, including 15.1% for integrated circuits and 13.6% for AI [5][6]. Group 2: Talent and Financial Support - Attracting high-quality talent is crucial for the success of the leading industries, as they are capital and talent-intensive. Shanghai aims to leverage its advantages to recruit top global tech talent, particularly in AI [6]. - Financial support from various sources, including government and private capital, is essential to stimulate the vitality of the leading industries and create a complete ecosystem for development [6]. Group 3: Robotics Industry Development - Shanghai is positioned to become a global hub for the robotics industry, with recommendations to establish a dedicated "Shanghai Robotics Industry Development Task Force" to coordinate planning and implementation [10]. - The robotics sector is transitioning from technology validation to large-scale application, necessitating a focus on core technology breakthroughs and the establishment of a competitive industrial ecosystem [11]. Group 4: Emerging Industries and Future Focus - The article highlights the importance of developing six emerging pillar industries and six future key sectors, advocating for a layered approach to advance mature sectors while nurturing growth and identifying frontier sectors [7]. - The low-altitude economy is identified as a new growth point, with a target industry scale of approximately 800 billion yuan by 2028, emphasizing innovation and application in this area [12][13]. Group 5: AI and Data Security - The rapid development of the AI industry is underscored, with a focus on the three elements of AI: computing power, algorithms, and data. The article notes the need for standardized systems in GPU and software development to support this growth [15][16]. - The integration of blockchain technology with AI is proposed as a means to ensure data security and compliance, highlighting potential opportunities in data processing services and compliance auditing tools [16].